Anatara’s IBS-D clinical trial to leverage Microba Life Sciences’ precision microbiome analysis

Precision microbiome science company, Microba Life Sciences , will work with Anatara Life Sciences (ASX:ANR) to complete microbiome analysis for a much-needed therapeutic treatment for sufferers of IBS-D. Anatara have commenced recruitment for a phase 1/2 clinical trial of their Gastrointestinal Re-Programming complementary medicine (GaRP) to address an unmet clinical need for IBS-D. Microba will apply its high-resolution gut microbiome analysis platform to measure the effect of the treatment on the microbiome by comparing pre-treatment specimens and specimens taken after eight weeks on the GaRP complementary medicine. Anatara has particular interest in this data as one of the mechanisms …

Read the source article at prwire.com.au
2021-08-22 17:16:00